中证智能财讯石药创新(300765)(300765)9月15日晚间公告,公司控股子公司石药集团(HK1093)巨石生物制药有限公司开发的SYS6010被国家药品监督管理局药品审评中心纳入突破性治疗品种名单,拟定适应症为免疫及含铂化疗治疗失败的复发或转移性驱动基因阴性非鳞非小细胞肺癌。据公告,该药物为靶向表皮生长因子受体(EGFR)的抗体偶联药物(ADC),由人源化抗EGFR单克隆抗体通过可裂解...
Source Link中证智能财讯石药创新(300765)(300765)9月15日晚间公告,公司控股子公司石药集团(HK1093)巨石生物制药有限公司开发的SYS6010被国家药品监督管理局药品审评中心纳入突破性治疗品种名单,拟定适应症为免疫及含铂化疗治疗失败的复发或转移性驱动基因阴性非鳞非小细胞肺癌。据公告,该药物为靶向表皮生长因子受体(EGFR)的抗体偶联药物(ADC),由人源化抗EGFR单克隆抗体通过可裂解...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.